Replies to post #109418 on Biotech Values

[DewDiligence]

There are four main cases to consider with respect to Copaxone:

1. FDA approves ANDA while patent case is still in litigation; NVS/MNTA launch “at risk.”

2. FDA approves ANDA while patent case is still in litigation; NVS/MNTA decide not to launch.

3. Patent case decided in NVS/MNTA’s favor while FDA review of ANDA is still pending.

4. Patent case decided in Teva’s favor while FDA review of ANDA is still pending.